{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:47:48Z","timestamp":1769161668447,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the diagnostic and prognostic value of osteopontin in patients with acute dyspnoea and\/or peripheral oedema suspected of having acute congestive heart failure (aCHF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A total of 401 patients presenting with acute dyspnoea and\/or peripheral oedema to the emergency department were prospectively enrolled and followed up for up to 5 years. Blood samples for biomarker measurements were collected on admission to the emergency department. Osteopontin combined with NT-proBNP vs. NT-proBNP alone for diagnosis of aCHF was tested. Additionally, osteopontin vs. NT-proBNP for prognostic outcomes (i.e. all-cause mortality, aCHF-related rehospitalization, and both in combination) was tested. The diagnostic and prognostic capacity of osteopontin was tested by C-statistics, reclassification indices, and multivariable Cox prediction models. Osteopontin plus NT-proBNP improved the diagnostic capacity for aCHF diagnosis [accuracy 76%, 95% confidence interval (CI) 72\u201380%; specificity 74%, 95% CI 69\u201379%, net reclassification improvement (NRI) +0.10] compared with NT-proBNP alone in the emergency department (P = 0.0001). Osteopontin independently predicted all-cause mortality and aCHF-related rehospitalization after 1 and 5 years. Compared with NT-proBNP, osteopontin was of superior prognostic value, specifically in aCHF patients and for the prognostic outcome of aCHF-related rehospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Osteopontin improves aCHF diagnosis when combined with NT-proBNP. Osteopontin identifies aCHF patients with high 1- and 5-year mortality and rehospitalization risk, and adds prognostic value to NT-proBNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT00143793<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hft112","type":"journal-article","created":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T21:38:07Z","timestamp":1373665087000},"page":"1390-1400","source":"Crossref","is-referenced-by-count":32,"title":["Diagnostic and Prognostic Value of Osteopontin in Patients with Acute Congestive Heart Failure"],"prefix":"10.1093","volume":"15","author":[{"given":"Michael","family":"Behnes","sequence":"first","affiliation":[{"name":"First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]},{"name":"Boehringer Ingelheim GmbH & Co. KG , Ingelheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"Lang","sequence":"additional","affiliation":[{"name":"First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Espeter","sequence":"additional","affiliation":[{"name":"First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department for Statistical Analysis, Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Neumaier","sequence":"additional","affiliation":[{"name":"Institute for Clinical Chemistry, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parviz","family":"Ahmad-Nejad","sequence":"additional","affiliation":[{"name":"Institute for Microbiology and Laboratory Medicine, HELIOS Klinikum Wuppertal, University of Witten\/Herdecke , Wuppertal ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Borggrefe","sequence":"additional","affiliation":[{"name":"First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,2,7]]},"reference":[{"key":"2026011921162769000_ejhfhft112-bib-0001","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0140-6736(06)68074-4","article-title":"Controversies in ventricular remodelling","volume":"367","author":"Opie","year":"2006","journal-title":"Lancet"},{"key":"2026011921162769000_ejhfhft112-bib-0002","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/ATVBAHA.107.144824","article-title":"Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease","volume":"27","author":"Scatena","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026011921162769000_ejhfhft112-bib-0003","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.RES.0000249379.55535.21","article-title":"Vascular calcification: pathobiological mechanisms and clinical implications","volume":"99","author":"Johnson","year":"2006","journal-title":"Circ Res"},{"key":"2026011921162769000_ejhfhft112-bib-0004","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1161\/01.HYP.0000148458.03202.48","article-title":"Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice","volume":"44","author":"Xie","year":"2004","journal-title":"Hypertension"},{"key":"2026011921162769000_ejhfhft112-bib-0005","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1161\/01.CIR.96.9.3063","article-title":"Myocardial osteopontin expression is associated with left ventricular hypertrophy","volume":"96","author":"Graf","year":"1997","journal-title":"Circulation"},{"key":"2026011921162769000_ejhfhft112-bib-0006","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/hh1001.090842","article-title":"Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin","volume":"88","author":"Trueblood","year":"2001","journal-title":"Circ Res"},{"key":"2026011921162769000_ejhfhft112-bib-0007","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/01.HYP.33.2.663","article-title":"Myocardial osteopontin expression coincides with the development of heart failure","volume":"33","author":"Singh","year":"1999","journal-title":"Hypertension"},{"key":"2026011921162769000_ejhfhft112-bib-0008","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/eurheartj\/ehr119","article-title":"Regulation of adverse remodelling by osteopontin in a genetic heart failure model","volume":"33","author":"Psarras","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011921162769000_ejhfhft112-bib-0009","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/eurjhf\/hfs179","article-title":"Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure","volume":"15","author":"Kaye","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011921162769000_ejhfhft112-bib-0010","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011921162769000_ejhfhft112-bib-0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijcard.2008.03.045","article-title":"Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema","volume":"135","author":"Behnes","year":"2009","journal-title":"Int J Cardiol"},{"key":"2026011921162769000_ejhfhft112-bib-0012","first-page":"557","article-title":"Association of NT-proBNP with severity of heart valve disease in a medical patient population presenting with acute dyspnea or peripheral edema","volume":"17","author":"Behnes","year":"2008","journal-title":"J Heart Valve Dis"},{"key":"2026011921162769000_ejhfhft112-bib-0013","article-title":"2013 ACCF\/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026011921162769000_ejhfhft112-bib-0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ejechocard\/jep007","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"10","author":"Nagueh","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"2026011921162769000_ejhfhft112-bib-0015","volume-title":"\u00a9 2010 R&D Systems","author":"Human Osteopontin (OPN) Quantikine ELISA Kit"},{"key":"2026011921162769000_ejhfhft112-bib-0016","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1148\/radiology.148.3.6878708","article-title":"A method of comparing the areas under receiver operating characteristic curves derived from the same cases","volume":"148","author":"Hanley","year":"1983","journal-title":"Radiology"},{"issue":"157\u2013172","key":"2026011921162769000_ejhfhft112-bib-0017","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/sim.3106","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"2026011921162769000_ejhfhft112-bib-0018","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1365-2362.2012.02671.x","article-title":"Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension","volume":"42","author":"Rosenberg","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"2026011921162769000_ejhfhft112-bib-0019","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCHEARTFAILURE.107.746172","article-title":"Osteopontin, a new prognostic biomarker in patients with chronic heart failure","volume":"1","author":"Rosenberg","year":"2008","journal-title":"Circ Heart Fail"},{"key":"2026011921162769000_ejhfhft112-bib-0020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijcard.2011.12.108","article-title":"Osteopontin (OPN) improves risk stratification in pulmonary hypertension (PH)","volume":"155","author":"Rosenberg","year":"2012","journal-title":"Int J Cardiol"},{"key":"2026011921162769000_ejhfhft112-bib-0021","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1161\/CIRCHEARTFAILURE.110.960716","article-title":"Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy","volume":"4","author":"Krum","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026011921162769000_ejhfhft112-bib-0022","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijcard.2010.08.048","article-title":"Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure","volume":"153","author":"Francia","year":"2011","journal-title":"Int J Cardiol"},{"key":"2026011921162769000_ejhfhft112-bib-0023","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.healun.2011.03.015","article-title":"Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support","volume":"30","author":"Schipper","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"2026011921162769000_ejhfhft112-bib-0024","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/eurjhf\/hfr079","article-title":"Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?","volume":"13","author":"Collier","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026011921162769000_ejhfhft112-bib-0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/CRD.0b013e3181cfb646","article-title":"Osteopontin in cardiovascular disease: a potential therapeutic target","volume":"18","author":"Waller","year":"2010","journal-title":"Cardiology Rev"},{"key":"2026011921162769000_ejhfhft112-bib-0026","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1388-9842(01)00237-9","article-title":"Increased myocardial expression of osteopontin in patients with advanced heart failure","volume":"4","author":"Stawowy","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"2026011921162769000_ejhfhft112-bib-0027","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10741-010-9158-6","article-title":"Role of osteopontin in heart failure associated with aging","volume":"15","author":"Singh","year":"2010","journal-title":"Heart Fail Rev"},{"key":"2026011921162769000_ejhfhft112-bib-0028","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jacc.2010.02.025","article-title":"Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial","volume":"55","author":"Maisel","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011921162769000_ejhfhft112-bib-0029","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/eurjhf\/hfr047","article-title":"Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure","volume":"13","author":"Pascual-Figal","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026011921162769000_ejhfhft112-bib-0030","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/eurjhf\/hfr087","article-title":"Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial","volume":"13","author":"Maisel","year":"2011","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhft112","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hft112","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hft112","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/12\/1390\/66441922\/eurjhf_15_12_1390.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/12\/1390\/66441922\/eurjhf_15_12_1390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:20:26Z","timestamp":1768875626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/15\/12\/1390\/8428812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,1]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,2,7]]},"published-print":{"date-parts":[[2013,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hft112","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,12]]},"published":{"date-parts":[[2013,12,1]]}}}